Investigational drug · Phase 3
Olverembatinib
Not approved by FDA. In 4 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Ph+ ALL, Leukemia, Lymphoblastic, Acute, Philadelphia-Positive, Relapsed/Refractory Acute Myeloid Leukaemia.
Phase 3Last checked: Nov 20, 2026Latest source record: Sep 15, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
4
4 still active
All registered trials
38
Any phase or sponsor naming "Olverembatinib"
First trial start
2020
Sep 28, 2020
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Olverembatinib", any sponsor or status.
Conditions studied
As listed on its trial records.
- Ph+ ALL
- Leukemia, Lymphoblastic, Acute, Philadelphia-Positive
- Relapsed/Refractory Acute Myeloid Leukaemia
- Myeloid Malignancy
- Chronic Myeloid Leukemia
- CML
- CML, Chronic Phase
- GIST
Approved drugs for the same conditions: Chronic myeloid leukemia · Hematology and blood cancers
Largest trials
Live from ClinicalTrials.gov: studies naming "Olverembatinib" as an intervention, largest first.
Ascentage Pharma Group Inc.Industry
NCT04501120 · 682 participants (planned) · Start Sep 28, 2020 · Primary completion Sep 2028
Drug: Lisaftoclax (APG-2575); Reduced-dose HHT and 4 more · For: Relapsed/Refractory Acute Myeloid Leukaemia; Myeloid Malignancy
Sites: Beijing, China; Chongqing, China; Guangzhou, China · 12 sites in all
- A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ ALL (POLARIS-1)Pivotal-lookingRecruiting
Ascentage Pharma Group Inc.Industry
NCT06051409 · 350 participants (planned) · Start Aug 31, 2023 · Primary completion Dec 31, 2027
Drug: Olverembatinib; Investigator's choice of TKI · For: Ph+ ALL; Leukemia, Lymphoblastic, Acute, Philadelphia-Positive
Sites: Birmingham, Alabama; Duarte, California; Los Angeles, California · 90 sites in all
- Study of Olverembatinib (HQP1351) in Patients With CML-CPPivotal-lookingRecruiting
Ascentage Pharma Group Inc.Industry
NCT06423911 · 333 participants (planned) · Start Feb 5, 2024 · Primary completion Jun 30, 2027
Drug: olverembatinib; Bosutinib · For: Chronic Myeloid Leukemia; CML; CML, Chronic Phase
Sites: Birmingham, Alabama; Anchorage, Alaska; Goodyear, Arizona · 163 sites in all
- De-escalation Strategy of Tyrosine Kinase Inhibitors Before Treatment Discontinuation in Patients With Chronic Myeloid LeukemiaPivotal-lookingNot yet recruiting
Nanfang Hospital, Southern Medical UniversityAcademic, hospital or other
NCT07839988 · 280 participants (planned) · Start Sep 9, 2026 · Primary completion Jul 31, 2030
Drug: Halve TKIs; Withdrawal TKIs · For: Chronic Myeloid Leukemia in Chronic Phase
Sites: Guangzhou, China
- Newly-diagnosed Pediatric Ph-positive B-ALL ProtocolPivotal-lookingRecruiting
Institute of Hematology & Blood Diseases Hospital, ChinaAcademic, hospital or other
NCT07152041 · 150 participants (planned) · Start Mar 28, 2025 · Primary completion Dec 2029
Drug: olverembatinib · For: Acute Lymphoblastic Leukemia (ALL) Philadelphia Chromosome-positive (Ph+); Childhood Leukemia, Acute Lymphoblastic
Sites: Hefei, China; Chongqing, China; Fuzhou, China · 24 sites in all
- A Pivotal Study of HQP1351 in Patients With Chronic Myeloid Leukemia in Chronic PhasePivotal-lookingCompleted
Ascentage Pharma Group Inc.Industry
NCT04126681 · 144 participants · Start Oct 21, 2019 · Primary completion Aug 1, 2024
Drug: HQP1351; Hydroxyurea or Interferon-based therapy and 2 more · For: Chronic Myeloid Leukemia, Chronic Phase
Sites: Beijing, China; Guangzhou, China; Shenzhen, China · 22 sites in all
- Chemotherapy With Targeted-Immunotherapy for Newly Diagnosed Ph+ ALLPivotal-lookingRecruiting
Institute of Hematology & Blood Diseases Hospital, ChinaAcademic, hospital or other
NCT07493161 · 110 participants (planned) · Start Apr 10, 2026 · Primary completion Mar 31, 2028
Drug: Olverembatinib; Venetoclax and 3 more · For: Ph+ ALL
Sites: Tianjin, China
- A Study of HQP1351 in Patients With GIST or Other Solid TumorsPivotal-lookingRecruiting
Ascentage Pharma Group Inc.Industry
NCT03594422 · 100 participants (planned) · Start Jul 11, 2018 · Primary completion Dec 2027
Drug: HQP1351 · For: Gastrointestinal Stromal Tumor (GIST); Solid Tumor, Adult
Sites: Guangzhou, China; Zhengzhou, China; Wuhan, China · 6 sites in all
- Observational Study on Dose Optimization of Olverembatinib in Patients With Chronic Myeloid Leukemia in Chronic or Accelerated PhaseEnrolling by invitation
Qian JiangAcademic, hospital or other
NCT07383298 · 100 participants (planned) · Start Dec 16, 2025 · Primary completion Dec 31, 2028
Drug: Olverembatinib 20mg · For: Chronic Myeloid Leukemia
Sites: Beijing, China
Institute of Hematology & Blood Diseases Hospital, ChinaAcademic, hospital or other
NCT07454226 · 92 participants (planned) · Start May 30, 2026 · Primary completion Mar 1, 2028
Drug: Olverembatinib; Gecacitinib and 3 more · For: Ph-Like; Acute Lymphoblastic Leukemia
Sites: Tianjin, China
Newest research
PubMed records naming it or its code names, newest first.
- Genomic and transcriptomic features associated with responses and outcomes of third-generation tyrosine kinase-inhibitor therapy in chronic myeloid leukemia.
Zhang X, Yu L, Li Z, et al. · Leukemia 2026
- Emerging BCR::ABL1 inhibitors in chronic myeloid leukemia: current advances and future directions.
Motomura Y, Sasaki K · Int J Hematol 2026
- Dissecting the binding landscape of four cKIT inhibitors through an integrated multifaceted approach.
Cipollone I, Gratteri C, Talarico C, et al. · Int J Biol Macromol 2026
- Venetoclax combined with olverembatinib and prednisone as a frontline therapeutic strategy for Philadelphia chromosome-positive mixed-phenotype acute leukemia.
Li X, Zhou Y, Lin X, et al. · Blood Res 2026
- The evolving landscape of tyrosine kinase inhibitors in chronic-phase chronic myeloid leukemia: A 25-year journey.
Haddad FG, Lipton JH, Jabbour EJ, et al. · Blood Rev 2026
- Reframing chronic myeloid leukemia outcomes beyond survival: a perspective of quality of life and patient-centered data.
Lipton JH, Abruzzese E, Gale RP, et al. · Blood Rev 2026
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.